Literature DB >> 16781240

Effects of peripheral blood stem cell mobilization with granulocyte-colony stimulating factor and their transcoronary transplantation after primary stent implantation for acute myocardial infarction.

Clemens Steinwender1, Robert Hofmann, Jürgen Kammler, Alexander Kypta, Robert Pichler, Wilma Maschek, Gerhard Schuster, Christian Gabriel, Franz Leisch.   

Abstract

BACKGROUND: There is increasing evidence that transplantation of autologous stem cells improves cardiac function after acute myocardial infarction (AMI). For propagation of peripheral blood stem cells (PBSCs), application of granulocyte-colony stimulating factor (G-CSF) has been shown to be feasible, effective, and safe. We sought to evaluate a clinical and angiographic long-term safety profile of G-CSF application combined with transcoronary PBSC transplantation after recent stent implantation for AMI.
METHODS: In patients with AMI and successful primary stenting of the infarct-related coronary artery, pharmacological bone marrow stimulation with G-CSF was initiated on the second postinterventional day. At least after 4 days of G-CSF therapy, apheresis as well as transcoronary transplantation of PBSCs was performed. The PBSCs were infused via a balloon catheter which was inflated inside the stent. Ventriculography and quantitative coronary angiography were performed at baseline and after 6 months.
RESULTS: In the 20 patients who received PBSCs, mean left ventricular ejection fraction improved from 46.4% +/- 8.1% at baseline to 54.3% +/- 11% after 6 months (P < .001) because of an increase in systolic function in the infarct region. Control coronary angiography revealed a significant in-stent restenosis of the infarct-related coronary artery, defined as >50% stenosis, in 8 patients (40%), which was complicated by reinfarction in 2 patients (10%).
CONCLUSIONS: Transcoronary transplantation of G-CSF-mobilized PBSCs favorably influences cardiac function and can be performed without adverse periprocedural events. However, significant in-stent restenosis and reinfarction seem to occur frequently during the following 6 months.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16781240     DOI: 10.1016/j.ahj.2006.03.012

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  5 in total

Review 1.  Rebuilding the damaged heart: the potential of cytokines and growth factors in the treatment of ischemic heart disease.

Authors:  Nirat Beohar; Jonathan Rapp; Sanjay Pandya; Douglas W Losordo
Journal:  J Am Coll Cardiol       Date:  2010-10-12       Impact factor: 24.094

Review 2.  Therapeutic myocardial angiogenesis.

Authors:  Marie-Ange Renault; Douglas W Losordo
Journal:  Microvasc Res       Date:  2007-09-07       Impact factor: 3.514

3.  In-stent restenosis in bare metal stents versus sirolimus-eluting stents after primary coronary intervention for acute myocardial infarction and subsequent transcoronary transplantation of autologous stem cells.

Authors:  Clemens Steinwender; Robert Hofmann; Alexander Kypta; Juergen Kammler; Klaus Kerschner; Michael Grund; Kurt Sihorsch; Christian Gabriel; Franz Leisch
Journal:  Clin Cardiol       Date:  2008-08       Impact factor: 2.882

4.  Cardiac Nerve Growth Factor Overexpression Induces Bone Marrow-derived Progenitor Cells Mobilization and Homing to the Infarcted Heart.

Authors:  Marco Meloni; Daniela Cesselli; Andrea Caporali; Giuseppe Mangialardi; Elisa Avolio; Carlotta Reni; Orazio Fortunato; Stefania Martini; Paolo Madeddu; Marco Valgimigli; Evgeni Nikolaev; Leszek Kaczmarek; Gianni D Angelini; Antonio P Beltrami; Costanza Emanueli
Journal:  Mol Ther       Date:  2015-09-10       Impact factor: 11.454

5.  G-CSF Predicts Cardiovascular Events in Patients with Stable Coronary Artery Disease.

Authors:  Katharina M Katsaros; Walter S Speidl; Svitlana Demyanets; Stefan P Kastl; Konstantin A Krychtiuk; Anna Wonnerth; Gerlinde Zorn; Ioannis Tentzeris; Serdar Farhan; Gerald Maurer; Johann Wojta; Kurt Huber
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.